ARTICLE | Distillery Therapeutics
Therapeutics: Discoidin domain receptor tyrosine kinase 1 (DDR1)
January 21, 2016 8:00 AM UTC
Cell culture and mouse studies suggest inhibiting DDR1 could help treat cancers resistant to RG7787. In an RG7787-resistant human skin cancer cell line, RG7787 combined with a DDR1 inhibitor increased cell death compared with RG7787 alone. In mouse xenograft models of RG7787-resistant skin and pancreatic cancers, the combination decreased tumor growth compared with either treatment alone or vehicle. Next steps could include testing DDR1 inhibition in models of other RG7787-resistant cancers...